NewLimit, based by Coinbase CEO Brian Armstorng, raises $130M to develop age-reversing therapies

[ad_1] NewLimit, a startup that goals to extend how lengthy folks can reside a wholesome life by genetically programming their cells, has raised a $130 million Sequence B led by Kleiner Perkins.

New traders Nat Friedman, Daniel Gross, and Khosla Ventures additionally invested, as did returning backers Founders Fund, Dimension Capital, Elad Gil, Garry Tan, Patrick Collison and others. The fundraise comes two years after the corporate raised a $40 million Sequence A.

Based over 4 years in the past by Coinbase CEO Brian Armstrong (pictured above), former GV companion Blake Bryers, and stem cell professor Jacob Kimmel, NewLimit claims it has made important progress in the direction of growing therapies that may restore youthful traits to aged cells.

Bryers instructed TechCrunch the corporate has found three prototype medicines that reprogram liver cells. NewLimit’s lab experiments, he stated, reveal this rejuvenation can restore the cells’ skill to course of fats and alcohol.

The corporate measures its progress by contrasting how cells from a youthful particular person and an older individual reply to the substances. An older liver cell that has gone by way of NewLeaf’s epigenetic reprogramming behaves extra like a youthful cell, Bryers stated.

Promising early outcomes however, NewLimit continues to be just a few years away from beginning human trials.

Within the meantime, the corporate needs to proceed growing new anti-ageing drugs utilizing an AI mannequin after which testing essentially the most promising of those machine-generated medicine in its laboratory. “What the AI mannequin permits us to do is run all these experiments in simulation after which solely observe up on essentially the most promising subset,” Bryers stated, including that the information factors from the experiment are then used to retrain the AI mannequin in a course of referred to as “lab in a loop.”

Techcrunch occasion

Berkeley, CA | June 5

BOOK NOW

Different noteworthy biotech startups growing medicine that purpose to extend lifespan embrace Retro Biosciences, which raised $180 million from OpenAI CEO Sam Altman two years in the past and is reportedly elevating a $1 billion Sequence A; and Altos Labs, which launched with $3 billion in 2022, and is backed by Jeff Bezos.